1′-substituted carba-nucleoside analogs for antiviral treatment

Patent metadata

Field	Value
Publication number	US-RE46762-E
Application number	US-201615288271-A
Country	US
Kind code	E1
Filing date	Oct 7, 2016
Priority date	Apr 23, 2008
Publication date	Mar 27, 2018
Grant date	Mar 27, 2018

Abstract

Provided are pyrrolo[1,2-f][1,2,4]triazinyl, imidazo[1,5-f][1,2,4]triazinyl, imidazo[1,2-f][1,2,4]triazinyl, and [1,2,4]triazolo[4,3-f][1,2,4]triazinyl nucleosides, nucleoside phosphates and prodrugs thereof, wherein the 1′ position of the nucleoside sugar is substituted. The compounds, compositions, and methods provided are useful for the treatment of Flaviviridae virus infections, particularly hepatitis C infections.

First claim

What is claimed is:

1. A compound of Formula II:

or a pharmaceutically acceptable salt, thereof;

wherein:
R 1 , R 3 , and R 5 are H;
R 2 and R 4 are, independently, OR a ;
R 6 is OR a , N 3 , CN, S(O) n R a , —C(═O)R 11 , —C(═O)OR 11 , —C(═O)NR 11 R 12 , —C(═O)SR 11 , —S(O)R 11 , —S(O) 2 R 11 , —S(O)(OR 11 ), —S(O) 2 (OR 11 ), —SO 2 NR 11 R 12 , halogen, substituted methyl, ethenyl, substituted ethenyl, ethynyl, or substituted ethynyl;
each n is independently 0, 1, or 2;
each R a is independently H, (C 1 -C 8 )alkyl, (C 2 -C 8 )alkenyl, (C 2 -C 8 )alkynyl, aryl(C 1 -C 8 )alkyl, (C 4 -C 8 )carbocyclylalkyl, —C(═O)R 11 , —C(═O)OR 11 , —C(═O)NR 11 R 12 , C(═O)SR 11 , S(O)R 11 , —S(O) 2 R 11 , —S(O)(OR 11 ), —S(O) 2 (OR 11 ), or —SO 2 NR 11 R 12 ;
R 7 is H, —C(═O)R 11 , —C(═O)OR 11 , —C(═O)NR 11 R 12 , —C(═O)SR 11 , —S(O)R 11 , —S(O) 2 R 11 , —S(O)(OR 11 ), —S(O) 2 (OR 11 ), —SO 2 NR 11 R 12 , or

W 1 and W 2 , when taken together, are —Y 3 (C(R y ) 2 ) 3 Y 3 —; or W 1 and W 2 are each, independently, a group of the Formula Ia:

Y and each Y 1 are independently O, S, NR, + N(O)(R) + N(O − )(R), N(OR), + N(O)(OR) + N(O − )(OR), or N—NR 2 ;
each Y 2 is independently a bond, O, CR 2 , NR, + N(O)(R) + N(O − )(R), N(OR), + N(O)(OR) + N(O − )(OR), N—NR 2 , S, S—S, S(O), or S(O) 2 ;
each Y 3 is independently O, S, or NR;
M2 is 0, 1 or 2;
each R x is independently R y or the formula:

wherein:
each M1a, M1c, and M1d is independently 0 or 1;
M12c is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12;
each R y is independently H, F, Cl, Br, I, OH, R, —C(═Y 1 )R, —C(═Y 1 )OR, —C(═Y 1 )N(R) 2 , —N(R) 2 , —+N(R) 3 — + N(R) 3 , —SR, —S(O)R, —S(O) 2 R, —S(O)(OR), —S(O) 2 (OR), —OC(═Y 1 )R, —OC(═Y 1 )OR, —OC(═Y 1 )(N(R) 2 ), —SC(═Y 1 )R, —SC(═Y 1 )OR, —SC(═Y 1 )(N(R) 2 ), —N(R)C(═Y 1 )R, —N(R)C(═Y 1 )OR, —N(R)C(═Y 1 )N(R) 2 , —SO 2 NR 2 , —CN, —N 3 , —NO 2 , —OR, or W 3 ; or when taken together, two R y on the same carbon atom form a carbocyclic ring of 3 to 7 carbon atoms;
each R is independently H, (C 1 -C 8 ) alkyl, (C 1 -C 8 ) substituted alkyl, (C 2 -C 8 )alkenyl, (C 2 -C 8 ) substituted alkenyl, (C 2 -C 8 ) alkynyl, (C 2 -C 8 ) substituted alkynyl, C 6 -C 20 aryl, C 6 -C 20 substituted aryl, C 2 -C 20 heterocyclyl, C 2 -C 20 substituted heterocyclyl, arylalkyl or substituted arylalkyl;
W 3 is W 4 or W 5 ; W 4 is R, —C(Y 1 )R y , —C(Y 1 )W 5 , —SO 2 R y , or —SO 2 W 5 ; and W 5 is a carbocycle or a heterocycle wherein W 5 is independently substituted with 0 to 3 R y groups;
X 2 is C—R 10 and X 1 is C—R 10 or N;
R 8 is halogen, NR 11 R 12 , N(R 11 )OR 11 , NR 11 NR 11 R 12 , N 3 , NO, NO 2 , CHO, CN, —CH(═NR 11 ), —CH═NHNR 11 , —CH═N(OR 11 ), —CH(OR 11 ) 2 , —C(═O)NR 11 R 12 , —C(═S)NR 11 R 12 , —C(═O)OR 11 , (C 1 -C 8 )alkyl, (C 2 -C 8 )alkenyl, (C 2 -C 8 )alkynyl, (C 4 -C 8 )carbocyclylalkyl, optionally substituted aryl, optionally substituted heteroaryl, —C(═O)(C 1 -C 8 )alkyl, —S(O) n C 1 -C 8 )alkyl —S(O) n (C 1 -C 8 )alkyl, aryl(C 1 -C 8 )alkyl, OR 11 or SR 11 ;
R 9 and each R 10 are independently H, halogen, NR 11 R 12 , N(R 11 )OR 11 , NR 11 NR 11 R 12 , N 3 , NO, NO 2 , CHO, CN, —CH(═NR 11 ), —CH═NHNR 11 , —CH═N(OR 11 ), —CH(OR 11 ) 2 , —C(═O)NR 11 R 12 , —C(═S)NR 11 R 12 , —C(═O)OR 11 , R 11 , OR 11 or SR 11 ;
each R 11 and each R 12 are independently H, (C 1 -C 8 )alkyl, (C 2 -C 8 )alkenyl, (C 2 -C 8 )alkynyl, (C 4 -C 8 )carbocyclylalkyl, optionally substituted aryl, optionally substituted heteroaryl, —C(═O)(C 1 -C 8 )alkyl, —S(O) n (C 1 -C 8 )alkyl or aryl(C 1 -C 8 )alkyl; or R 11 and R 12 taken together with a nitrogen to which they are both attached to form a 3 to 7 membered heterocyclic ring wherein any one carbon atom of said heterocyclic ring can optionally be replaced with —O—, —S— or —NR a —;
wherein substituted methyl, substituted ethenyl and substituted ethynyl of R 6 and each (C 1 -C 8 )alkyl, (C 2 -C 8 )alkenyl, (C 2 -C 8 )alkynyl or aryl(C 1 -C 8 )alkyl of each of R 11 and R 12 are independently, optionally substituted with one or more halo, hydroxy, CN, N 3 , N(R a ) 2 or OR a ; and
wherein one or more of the non-terminal carbon atoms of each said (C 1 -C 8 )alkyl is optionally replaced with —O—, —S— or —NR a —.

2. The compound according to claim 1 , wherein R 6 is OR a , N 3 , halogen, CN, substituted methyl, ethenyl, substituted ethenyl, ethynyl, or substituted ethynyl.

3. The compound according to claim 1 , wherein R 2 and R 4 are OH.

4. The compound according to claim 2 , wherein R 2 and R 4 are OH.

5. The compound according to claim 1 , wherein R 6 is CN.

6. The compound according to claim 4 , wherein R 6 is CN.

7. The compound according to claim 4 , wherein R 9 is NR 11 R 12 .

8. The compound according to claim 7 , wherein X 2 is C—H.

9. The compound according to claim 8 , wherein X 1 is C—H.

10. The compound according to claim 9 , wherein R 7 is H.

11. The compound according to claim 9 , wherein

12. A compound selected from the group consisting of

or a pharmaceutically acceptable salt thereof.

13. A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 1 and a pharmaceutically acceptable carrier.

14. The pharmaceutical composition of claim 13 further comprising at least one additional therapeutic agent selected from the group consisting of interferons, ribavirin analogs, NS3 protease inhibitors, NS5a inhibitors, NS5b polymerase inhibitors, alphaglucosidase alpha-glucosidase 1 inhibitors, cyclophilin inhibitors, hepatoprotectants, non-nucleoside inhibitors of HCV, and other drugs for treating HCV.

15. A method of inhibiting HCV polymerase comprising administering to a mammal in need thereof a therapeutically effective amount of a compound of claim 1 .

16. A method of treating a viral infection caused by a virus selected from the group consisting of dengue virus, yellow fever virus, West Nile virus, Japanese encephalitis virus, tick-borne encephalitis virus, Kunjin virus, Murray Valley encephalitis virus, St. Louis encephalitis virus, Omsk hemorrhagic fever virus, bovine viral diarrhea virus, Zika virus and Hepatitis C virus comprising administering to a mammal in need thereof a therapeutically effective amount of a compound or pharmaceutical composition of claim 1 .

17. The method of claim 16 , wherein the viral infection is caused by Hepatitis C virus.

18. The method of claim 17 further comprising administering at least one additional therapeutic agent selected from the group consisting of interferons, ribavirin analogs, NS3 protease inhibitors, NS5b polymerase inhibitors, NS5a inhibitors, alpha-glucosidase 1 inhibitors, cyclophilin inhibitors, hepatoprotectants, non-nucleoside inhibitors of HCV, and other drugs for treating HCV.

Assignees

• Gilead Sciences Inc
• Gilead Sciences Inc

Inventors

• Butler Thomas
• Cho Aesop
• Kim Choung U
• Parrish Jay P
• Saunders Oliver L
• Zhang Lijun

Classifications

• A61P31/20

  for DNA viruses · CPC title

• A61P31/14

  for RNA viruses · CPC title

• A61P31/12

  Antivirals · CPC title

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P31/16

  for influenza or rhinoviruses · CPC title